1 As of 2016, this webpage is unfortunately no longer in operation. The Lilab lost the server for this webpage in 2014 and has not restored it since. They can provide the algorithms for the SH2 domain-binding motifs upon request. These motifs may be used for searching via other search engines, such as ScanSite. The alternative search, interrogating one and one protein by a domain scan, is still operable: http://lilab. uwo.ca/cgi-bin/SMALI_domain_search.pl
Introduction
T cell-specific adaptor protein (TSAd) encoded by the SH2D2A gene is emerging as a regulator of cell migration, T cell activation and actin polymerization. TSAd contains several protein-binding domains, including an N-terminal Src homology 2 domain (SH2 domain), three C-terminal tyrosine phosphorylation sites and a C-terminal prolinerich region [1] . Several signalling proteins are known to bind to the proline-rich region and/or the pTyr of TSAd, including the Src family kinase Lck [2] [3] [4] , the Tec family Il2-inducible T cell kinase (Itk) [5] [6] [7] and the non-catalytic region of tyrosine kinase adaptor protein (Nck) [8] . However, so far, only the molecular motor valosincontaining protein (VCP) has been reported to be a direct ligand for the TSAd SH2 domain in T cells, where VCP has been suggested to be involved in nuclear import of TSAd [9] .
SH2 domains are well-conserved globular structures of approximately 100 amino acid residues, and include a phosphotyrosine recognition pocket [10] . The human genome encodes 120 SH2 domains distributed among 110 different proteins [11] . SH2 domains thereby constitute the largest family of interaction modules. SH2 domains mediate protein-protein interactions by typically binding to phosphorylated tyrosines and their flanking amino acids, providing phosphorylation-dependent and sequence-specific interaction.
The isolated TSAd SH2 domain works as a dominant negative of TSAd, as TSAd SH2-transgenic mice have a similar phenotype as TSAd knock outs, including impaired T cell receptor (TCR)-mediated T cell proliferation and IL-2 production. This strongly indicates that the TSAd SH2 domain is important for TSAd function in T cells [7, 12] . Furthermore, TSAd molecules carrying a mutation in the pTyr-binding pocket of the TSAd SH2 domain (R120K) lack ability to enhance IL-2 gene expression [13] .
CD6 is a transmembrane surface glycoprotein expressed at high levels on mature T lymphocytes, and also on many B cell leukaemias and lymphomas [14] . Its extracellular ligand is CD166 (also known as activated leucocyte cell adhesion molecule, ALCAM). CD166 is expressed by antigen-presenting cells, activated leucocytes and thymic epithelial cells [15] . Upon binding of CD166 to CD6, both molecules localize to the immunological synapse, providing strength and stability between the T cell and antigenpresenting cell contact site as well as promoting cell proliferation [16] [17] [18] .
CD6 has a cytoplasmic tail of 244 amino acids containing numerous signalling motifs, including two PRR, nine Tyr residues and eleven Ser/Thr residues [19] . Following TCR triggering, CD6 is phosphorylated primarily on Tyr 629 and Tyr 662 [20, 21] . CD6 associates with several intracellular signalling molecules, including the tyrosine kinases Lck, Itk and ZAP-70 [22] . Moreover, the adaptor SH2 domain containing leucocyte protein of 76 kDa (SLP-76) binds to CD6 pTyr 662 through its SH2 domain [18] , leading to recruitment and activation of the MAPK cascades with phosphorylation of Erk1/2, p38 and JNK [23] . Involvement of CD6 in intracellular signalling pathways is poorly characterized, and its biological function remains controversial. Whether CD6 functions exclusively as a positive co-stimulatory molecule in TCR activation or as a modulator of intracellular signalling recruiting positive or negative effectors in different situations and thereby having a dual role is still unclear [19] .
Linker for activation of T cells (LAT) is a 36-to 38-kDa membrane-associated adaptor protein with a long cytoplasmic tail, which plays an important role in recruitment and assembly of multiple signalling effector proteins into the LAT signalosome. Upon TCR activation, LAT becomes phosphorylated on tyrosine residues at positions Tyr [24, 25] , leading to formation of signalling complexes containing GRB2-related adaptor downstream of Shc (GADS), phospholipase C, gamma 1 (PLCc1), SLP-76 and growth factor receptor-bound 2 (Grb2). SLP-76 is brought to the LAT complex via constitutive interaction with the GADS Src homology 3 (SH3) domain [26] [27] [28] whereby it recruits other effector molecules to the LAT signalosome, including Nck and Vav. Activation of the LAT signalosome drive downstream signalling leading to increased intracellular Ca 2+ , actin polymerization and change in gene expression by activation of transcription factors (nuclear factor kappa B (NF-jB), nuclear factor in activated T cells (NFAT) and activator protein 1 (AP-1) etc.)
In this study, we searched for novel ligands for the TSAd SH2 domain in T cells. Using an in silico approach based on the scoring matrix-assisted ligand identification SMALI algorithm [29, 30] , we identified phosphotyrosines of CD6 and LAT as potential novel TSAd SH2 domain ligands in T cells. Biochemical studies in Jurkat T cells, including pull-down and immunoprecipitation, confirmed the predicted interactions. TSAd is a well-established adaptor for Lck and Itk. The interaction of CD6 and LAT with TSAd may provide a novel link by which CD6 and LAT connect to intracellular signalling pathways.
Materials and Methods
Antibodies and reagents. The following monoclonal antibodies were used: anti-Gluthatione-S-transferase (GST) (B12) and anti-GFP (B-2) (Santa Cruz Biotechnology, Inc.), anti-CD6 (MEM-98) and anti-LAT (LAT-01) (ExBio), anti-TCR (C305; a gift from A. Weiss, University of California, San Francisco), anti-human CD3e (OKT3; American Type culture collection), antiphosphotyrosine (4G10; Upstate Biotechnology) and anti-HA (HA.11, Bio Site). The following polyclonal antibodies were used: antiTSAd antibody raised in rabbit against a synthetic peptide encompassing the 20 C-terminal amino acids [31] and isotype-matched IgG as described previously [1] . Secondary antibodies were horse radish peroxidase (HRP)-conjugated goat anti-mouse IgG, goat anti-mouse IgG light chainspecific and goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA).
Plasmids. The glutathione S-transferase (GST) construct of human wild-type TSAd SH2 was generated in the pGEx-6P-1vector (GE Healthcare) as previously described [32] . GFP-tagged CD6 constructs (CD6FL/pEGFPN1and CD6CY5/pcDNA3.1/CT-GFP-TOPO) were a generous gift from A. Carmo [33] . All constructs were verified by sequencing.
Expression and purification of fusion proteins. GST-TSAd SH2 domain fusion protein was produced in E.coli BL21-Codon Plus (DE)-RP (Stratagene) in M9 minimal salt media at 25°C to OD 600 = 0.6. Protein expression was induced at 4°C by addition of isopropyl-beta-D-thiogalactoside (IPTG) (Sigma-Aldrich) to a final concentration of 0.2 mM, followed by incubation at 15°C for 16 hours. Cultures were harvested by centrifugation at 4°C, lysed in PBS with 2.5 mg/ml lysozyme followed by one freezethaw cycle (at À80°C over night) and further lysis in GSTlysis buffer (1% Triton X-100, 1 mM DTT, 1 mM PMSF, 0.5 mg/ml lysozyme, 5 lg/ml DNase, PBS pH 7.4) for 16 h at 4°C with agitation. Following centrifugation, the recombinant protein was purified in bulk on Gluthatione 4B Sepharose beads (GE Healthcare), according to the manufacturer's instructions. Briefly, the lysate was precleared with 4B Sepharose beads (GE Healthcare) at 4°C with rotation for 3 h to minimize unspecific binding, prior to binding on Glutathione Sepharose TM 4 Fast Flow beads (GE Healthcare) at 4°C with rotation (~16 h). Beads were washed in PBS pH 7.4 and stored at À20°C in 60% glycerol in PBS pH 7.4. GST-TSAd SH2 was eluted from glutathione beads using glutathione as described by the manufacturer. Briefly, GST-TSAd SH2 was eluted in 50 mM Tris-HCl, pH 8.0, 10 mM reduced glutathione and 1 mM PMSF at 4°C~16 h. The purity of recombinant GST-TSAd SH2 was assessed by SDS-PAGE and Coomassie Brilliant Blue staining, and the concentration was measured by NanoDrop spectrophotometry (Thermo Fisher Scientific, Waltham, MA USA) at a wavelength of 280 nm and a theoretically determined extinction coefficient (ProtParam).
Cell cultures and transfections. Jurkat TAg cells [34] were cultured in complete RPMI 1640 medium (RPMI 1640 supplemented with 10% foetal bovine serum, 1 mM sodium pyruvate, 10 mM Hepes, 1 mM MEM non-essential amino acids, penicillin (100 U/ml), streptomycin (100 lg/ml) (GIBCOBRL â , Thermo Fischer Scientific) and 50 lM bmercaptoethanol (Sigma)). Transient transfections of 1.5 9 10 7 Jurkat cells in RPMI 1640 with 0.5-10 lg of plasmid DNA were performed using a BTX electroporator (Genetronix) at 240 V and 25 ms. Transfectants were cultured for 16-24 h in RPMI 1640 medium supplemented with 5% foetal bovine serum, 1 mM sodium pyruvate, 10 mM Hepes and 1 mM MEM non-essential amino acids.
Cell stimulation and lysis. For activation of Jurkat TAg cells, cells were washed with PBS, re-suspended to 1 9 10 8 cells/ml and stimulated with 5 lg/ml anti-CD3e (OKT3) for 2.5 min at 37°C. Alternatively, the cells were pervanadate treated for 5 min (0.01% H 2 O 2 and 100 lM Na 3 VO 4 ) at 37°C. Stimulation was ended by addition of ice-cold PBS and centrifugation. For pull-down experiments, cells were lysed in 19 lysis buffer: 1% Nonidet-P40, 50 mM n-octylb-D-glucoside (OGP), 25 mM Tris (pH 7.5), 100 mM NaCl, 20 mM NaF, 1 mM Na 3 VO 4 and 19 EDTA free protease inhibitor cocktail (Roche) for 30 min on ice. For immunoprecipitation (IP), reduced amounts of detergents were used: 0.25% Nonidet-P40 and 12.5 mM OGP.
Pull-down and immunoprecipitation. For pull-down experiments, cell lysates from 1.5 9 10
7 Jurkat TAg cells were precleared three times for 30 min at 4°C with a 2:1 mixture of GST/Glutathione Sepharose TM 4B beads (GE Healthcare). The supernatants were added to aliquots of Glutathione Sepharose TM 4 Fast Flow (GE Healthcare) coupled GST fusion proteins and rotated for 1 h at 4°C. For IP, Jurkat cell lysates were precleared three times for 30-45 min with Dynabeads Protein G (Life Technologies), and incubated with the relevant antibodies conjugated to Dynabeads Protein G (Life Technologies), for 1 or 16 h with rotation at 4°C. Beads from pull-down or IP were washed three times in 19 lysis buffer. Proteins were separated by SDS-PAGE and detected by immunoblotting with the relevant antibodies.
Western blot. Proteins were separated on SDS-PAGE and transferred to a PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA) using a Hoefer Semi-Phor Semi-Dry Transfer Unit (GE Healthcare, Little Chalfont, UK), or a Trans-Blot â Turbo TM Transfer System (Bio-Rad). Blots were blocked in TBS-T (pH 7.4, 0.1% Tween) with 3% skimmed milk (Sigma) or 3% bovine serum albumin (BSA; Biotest) and subsequently incubated with the indicated antibodies in blocking buffer. Signals were detected by horseradish peroxidase (HRP)-labelled secondary antibodies and SuperSignal Peptide spot array analysis. Peptide arrays were synthesized on nitrocellulose membranes using a MultiPep automated peptide synthesizer (INTAVIS Bioanalytical Instruments AG) as previously described [35] . Membranes were spotted with relevant phosphotyrosine peptides and probed with GST-tagged TSAd SH2 fusion proteins (80 lg/ml) followed by mouse anti-GST antibody and anti-mouse HRP secondary antibody. Signals were detected by chemiluminescent detection by SuperSignal â West Pico stable peroxide solution (Pierce). Statistical analysis. Quantitative data are shown as mean AE standard deviation. Statistical significance was defined as P-value <0.05 and was estimated by a two-tailed paired Student's t-test.
Results
In silico analysis identify CD6 and LAT as potential TSAd SH2 ligands TSAd contains an SH2 domain, as well as C-terminus with a proline-rich region and potential pTyr sites (Fig. 1A) . The C-terminus is known to interact with Lck, Itk and Nck. To identify ligands for the TSAd SH2 domain, we used the web-based SMALI algorithm [29, 30] as an initial approach. TSAd was used as a query protein in a SMALI peptide scan. A total of 100 potential interaction partners with a SMALI score >1.91 were identified (Table S1) . A SMALI score >1.0 strongly indicates potential binding between an SH2 domain and a phosphotyrosine ligand [30] . The top three candidates with the highest SMALI score values are shown in Table 1 . Among these top three, two are established TSAd SH2 domain interaction partners, VEGFR-2 in endothelial cells and PDGFR-b in lung epithelial cells [36] [37] [38] . PDGFR-b pTyr 775 was predicted to interact with TSAd SH2 with a SMALI score of 2.34, whereas VEGFR-2 pTyr 1214 was predicted with a score of 2.42. The association of TSAd SH2 with VEGFR-2 in endothelial cells has previously been reported to be with pTyr 951 [38] . SMALI failed to identify VEGFR-2 pTyr 951 as a potential interaction site.
Of genes specifically expressed in T cells, SMALI peptide scan identified the membrane-associated molecules LAT (pTyr 191 ) and CD6 (pTyr 629 ) with relative SMALI scores of 1.97 and 1.91, respectively ( Table 1) . As a next step to begin to explore these predicted TSAd SH2 interaction in T cells, we performed the reciprocal in silico approach and searched for SH2 domains which may interact with some of the hits listed in Table 1 . SMALI domain scans were thus performed with VEGFR-2, PDGFR-b, VCP, MEKK2, CD6 and LAT as query proteins. The predicted interactions with TSAd SH2 domain were in accordance with results from the peptide scan (Table 1 ). In addition, LAT pTyr 171 and pTyr 226 were also identified as possible ligands for the TSAd SH2 domain (Table 1 ). In both the peptide and domain scans, the SMALI algorithm failed to identify the known TSAd SH2 domain ligands VEGFR-2 pTyr 951 in endothelial cells [37] and VCP pTyr 805 in T cells [9] as interaction partners.
The TSAd SH2 domain interacts with CD6 and LAT pTyr peptides
To confirm the in silico-predicted interaction between the TSAd SH2 domain and CD6, phosphotyrosine peptides representing the two main tyrosine phosphorylation sites in the CD6 intracytoplasmic domain, CD6 pTyr 629 and CD6 pTyr 662 [20] , were spotted on a nitrocellulose membrane. A phosphopeptide representing VEGFR-2 pTyr 951 was included as positive control and the VEGFR-2 pTyr 801 as a negative control [38] . The membrane was incubated with GST-tagged TSAd SH2 domain, followed by detection of bound GST by anti-GST antibody. As predicted by the SMALI analysis, the CD6 pTyr 629 peptide revealed a strong GST signal, indicating direct binding of the GST-TSAd SH2 domain to this ligand. In contrast, the CD6 pTyr 662 peptide that was not predicted to bind to the TSAd SH2 domain by SMALI displayed a weak signal on the peptide array in comparison with the CD6 pTyr 629 peptide (Fig. 1B) . Additionally, recombinant GST-TSAd SH2 domain was found to interact with phosphotyrosine peptides of LAT. LAT phosphotyrosines, reported to be phosphorylated following TCR activation and required for normal T cell signalling and function (pTyr 132 , pTyr 171 , pTyr 191 and pTyr 226 ) [24, 39] , were included in the peptide array. LAT pTyr 45 was included as a negative control. Direct interaction between the TSAd SH2 domain and LAT pTyr 171 , pTyr 191 and pTyr 226 was detected (Fig. 1B) . In accordance with the TSAd SH2 motif identified by Huang and coworkers [30] , the phosphopeptides of LAT and CD6 found to interact with TSAd SH2 domain all contained N in P + 2 ( Fig. 1B and Table 1 ). However, as seen in Table 1 , TSAd SH2 may also bind to phosphopeptides lacking this motif.
Taken together, these data support the SMALIpredicted interactions, and point towards CD6 pTyr 629 and LAT pTyr 171 , pTyr 191 and pTyr 226 as being engaged in TSAd SH2 binding.
The TSAd SH2 domain interacts with CD6 and LAT in Jurkat T cells
Having identified CD6 and LAT as a potential interaction partner for the TSAd SH2 domain by an in silico and peptide array approach, we examined the interaction of the isolated TSAd SH2 domain with pTyr proteins in cell lysates. Indeed, the TSAd SH2 domain was found to interact with several phosphorylated proteins in pull-down assays from Jurkat cell lysates ( Fig. 2A) . GST alone was used as a negative control. TSAd SH2-interacting proteins were separated by SDS-PAGE and probed with antiphosphotyrosine antibody. Several phosphorylated proteins were shown to interact with TSAd SH2 both in nonstimulated, anti-CD3 (OKT3)-stimulated and pervanadate (PV)-treated cells. Control pull-downs with GST were negative (lanes 1, 3 and 5) (Fig. 2A) . Of the phosphotyrosine protein bands in the lysate, several were enriched by TSAd SH2 pull-down, including a prominent band3 ........................................................................................................................................................... .... with lane 9 right panel-short exposure) and two bands1 50 kDa irrespective of treatment (lanes 2 and 7 and lanes 4 and 8). The TSAd SH2 domain-interacting protein of 37 kDa could possibly be LAT as LAT is one of the most prominently tyrosine-phosphorylated proteins of that molecular weight following TCR activation [40, 41] .
Probing the TSAd SH2 pull-down blots with anti-LAT antibody indeed identified LAT as an interaction partner to TSAd SH2 ( Fig. 2A, middle panel) .
In Jurkat cells, LAT is present as two forms of 36 and 38 kDa. Both of these are phosphorylated, with the 36 kDa being the prominent tyrosine-phosphorylated form [42] . This is in accordance with our results, showing both bands in the Jurkat cell lysate. Tyrosine-phosphorylated LAT is not optimally recognized by the anti-LAT-01 antibody. Accordingly, we observed reduced LAT signal in lysates from stimulated cells and especially in PV-treated cells ( Fig. 2A, middle panel, compare lanes 7 and 9) . Despite this caveat, we detected LAT in pull-downs from both anti-CD3 and PV-treated cells, indicating enrichment of phosphorylated LAT among the proteins interacting with TSAd SH2 domain.
CD6 is expressed in low amounts in Jurkat cells [43] . To further investigate the potential TSAd-CD6 interaction, Jurkat cells were therefore transiently transfected with plasmids encoding GFP-tagged full length (FL) or truncated version of CD6 that lacked the cytoplasmic tail containing the phosphotyrosines with the putative SH2 domain interaction sites (CD6 DCyt) (Fig. 2B) . The GSTTSAd SH2 fusion protein associated with CD6 FL in unstimulated cells, and increased interaction was found after CD3 triggering. In contrast, CD6 DCyt did not interact with the TSAd SH2 domain (Fig. 2C) . Together, these results point to an interaction between the TSAd SH2 domain and the cytoplasmic tail of CD6.
TSAd co-immunoprecipitates with CD6 and LAT in Jurkat cells
To verify whether TSAd interacts with CD6 in cells, we performed anti-TSAd immunoprecipitations in cell lysates derived from Jurkat cells transiently expressing GFP-CD6 and HA-TSAd. Cells were transfected also with HA-tagged TSAd as also TSAd expression is low in non-stimulated Jurkat cells. To ensure maximal tyrosine phosphorylation of CD6, we treated the transfected cells with PV prior to lysis of the cells. CD6 co-precipitated with TSAd in both non-treated and PV-treated cells. Following PV treatment, increased interaction between TSAd and CD6 was observed (Fig. 3A) . Similarly, when the reciprocal experiment was performed with CD6 as the bait, TSAd co-precipitated with GFP-tagged CD6 in anti-GFP immunoprecipitations (Fig. 3B) . Tyr, tyrosine. Underlined Y represents phospho-Tyr. a Sun and co-workers used truncated versions of the MEKK2 protein to show interaction with TSAd, indirectly implicating MEKK2 Tyr 250 as a TSAd SH2 target. b GST-TSAd SH2 binds to MEKK2 pTyr250 (the given sequence motif) in peptide array (data not shown). c Not reported to be tyrosine phosphorylated in PhosphoSite [49] nor Phospho.ELM [50] . SMALI peptide scan results indicating score values for the predicted interaction between the TSAd SH2 domain and indicated tyrosines, including the top three hits. SMALI cut-off score = 1.91. Score values for domain scans predicting interactions with phosphotyrosines to the TSAd SH2 domain are presented (cut-off score =1.0). '-' indicates a SMALI score < cut-off.
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Further analysis of the interaction of LAT with TSAd by anti-TSAd immunoprecipitations from Jurkat cells transiently expressing HA-tagged TSAd showed interaction with endogenous LAT in both non-treated and PV-treated cells (Fig. 3C) . Upon PV treatment of cells, reduced LAT signal using the phosphotyrosine-sensitive LAT antibody LAT-01 was seen both in the lysate and in the immunoprecipitate. This reduced LAT signal upon PV treatment of the cells indicates the presence of hyperphosphorylated LAT (Fig. 3C) . However, when the amount of LAT was assessed based on relative strength of signal in the IP compared to that observed in the corresponding cell lysates, significantly more LAT was found to be associated with TSAd after PV treatment than after CD3 stimulation (Fig. 3D) . Taken together, our data support the notion that TSAd interacts with both LAT and CD6 in Jurkat cells and that these interactions are dependent on phosphorylated tyrosines on both LAT and CD6.
Discussion
The role of the adaptor TSAd in T cells is not fully characterized. Although it is well established that Lck and Itk interact with TSAd through the TSAd C-terminus, less is known about the role of the TSAd SH2 domain in T cells. Here, we provided evidence that TSAd interacts with LAT and CD6 via its SH2 domain.
We used in silico analysis, peptide arrays, pull-down assays and co-immunoprecipitation experiments to identify novel interaction partners for the TSAd SH2 domain. The peptide array data suggested a direct interaction between pTyr peptides of both CD6 (pTyr 629 ) and LAT (pTyr 171 , pTyr 191 and pTyr 226 ) with the TSAd SH2 domain. However, in vitro assays are usually set up under highly non-physiological conditions. Pull-down and immunoprecipitation experiments, using TSAd SH2 domain or TSAd full length, respectively, supported the peptide array data and showed that the interactions also occur in cell lysates. Although an indirect interaction cannot be ruled out, together our data point to a direct TSAd SH2 interaction to CD6 and LAT.
The specificity of 76 of the 120 human SH2 domains, including the TSAd SH2 domain was previously investigated by Huang and co-workers using an oriented peptide array library (OPAL). They reported that the TSAd SH2 domain-binding motif was X(H/E/P)pY(D/E/S)NX (where X could be any amino acid), with a strong preference for asparagine (N) in position +2 (P + 2) to the phosphotyrosine [30] . The phosphopeptides of LAT and CD6 found ............................................................................................................................................................... to interact with TSAd SH2 domain in our study all contain a pYXN motif (Table 1) . TSAd was previously found to interact with MEKK2 in epithelial and Jurkat cells.
Interestingly, the only possible ligand for TSAd within the TSAd interacting part of MEKK2 is MEKK2 pTyr 250 [44] . This tyrosine is also within a pYXN motif, again indicating a preference of TSAd SH2 for N in the P + 2 position. In support of this notion, the SMALI peptide scan predicted MEKK2 pTyr 250 to be a potential TSAd SH2 domain interaction partner. In fact, all the additional proteins listed among possible TSAd SH2 interacting partners by SMALI peptide scan exclusively included proteins with N in P + 2 (Table S1) .
Although the TSAd SH2 domain shows a strong preference for N in P + 2 according to the SMALI algorithm based on the OPAL screen [30] , the already established interaction partners for the TSAd SH2 domain, that is VEGFR-2 pTyr 951 and VCP pTyr 805 , do not possess N in P + 2 ( Table 1) . SMALI therefore failed to identify these as interaction partners for TSAd SH2. The SMALI algorithm is based on only one experimental set-up, the OPAL screen, which does not take into consideration nonpermissive amino acids [45] . Recently, a similar screen of phosphotyrosine sites reported in the PhoshoSite, Phospho.ELM or NetPhos databases, using a total of 70 SH2 domains, pointed to N in P + 2 as important for TSAd SH2 binding [46] .
Huang et al. classified TSAd SH2 domain to belong to the group 1C of SH2 domains. This group constitutes 18 members, including the Grb2/GADS family and ALX (a TSAd homologue) [30] . All 1C group members show a clear preference for an N residue at P + 2. An intriguing possibility is that TSAd could compete with Grb2 and/or GADS for binding partners depending on the stimulatory state of the cell. Both Grb2 SH2 and GADS SH2 are known to bind to the same LAT pTyr sites that were recognized by TSAd SH2 in the present study (both bind LAT pTyr 171 , pTyr 191 and Grb2 also bind LAT pTyr 226 ) [24, 39] . Whether TSAd binds with similar affinity to LAT as these two proteins needs further investigation. Also, whether all three molecules could bind simultaneously or sequentially to the same LAT molecule, or whether they are associated with different LAT molecules remains to be determined.
In line with the notion that TSAd may be a possible activation-induced competitor to other group 1C members in T cells, both Grb2, GADS and the TSAd homologue ALX or HSH2 [47] were predicted by SMALI domain scan to bind to CD6 pTyr 629 (data not shown). Whether any of these proteins are direct CD6 interaction partners remains to be established.
Our work reveals that the TSAd SH2 domain may have multiple interaction partners within T cells (Fig 2A) . There may be additional proteins that are equally or more important binding partners for TSAd SH2 than those reported here. LAT and CD6 were selected for further analysis based on in silico predictions and their known expression in T cells. Mass spectrometry analysis of TSAd SH2-interacting pTyr proteins may allow a more unbiased identification of additional interaction partners.
A recent report suggested that CD6 function as a LATindependent signalling hub, recruiting SLP-76 and Vav1 following TCR-mediated activation, irrespective of LAT [43] . Our finding that also TSAd interacts with both LAT and CD6 provide further support for the notion that these two membrane-associated molecules serve overlapping functions.
Phosphorylation of LAT is reduced, not abolished upon TCR activation in Zap70-or Syk-deficient cells, indicating that LAT is phosphorylated also by other kinases than Zap70 [41] . The Src family kinase Lck has been shown to phosphorylate LAT at Tyr 171 and Tyr 191 [25] , and to colocalize with LAT at the plasma membrane [41] . TSAd could be a mediator of Lck association with LAT. Additionally, TSAd interacts with Grb2 in lung epithelial cells [36] and with PLCc in endothelial cells [48] , both established interaction partners of LAT. In this respect, TSAd could be part of a larger LAT signalosome complex including Lck, Grb2 and PLCc.
Castro and co-workers [22] previously showed that the rat homologue of CD6 (OX52) interacts with both Lck and Itk in co-immunoprecipitation experiments. Whether or not the interaction between CD6 and Lck or Itk is direct or indirect via another protein has not been established. In this regard, TSAd might provide a possible link between CD6 and Lck or Itk, and thus intracellular signalling pathways controlled by either of these two kinases.
In conclusion, identification of CD6 and LAT as novel TSAd SH2 domain interaction partners provides novel clues to the role of TSAd in T cells. Further work is required to establish the relative importance of TSAd in LAT and CD6-nucleated signalosomes.
